SCHEMBL16620945

SCHEMBL16620945

CC=CC=CC=C(C#N)C#N

nearest known ligand 0.43

Predicted protein targets (top 3)

geneUniProtsupporting neighboursconfidence
▸ APP P05067 4/20 0.43
▸ ALDH1A1 P00352 1/20 0.33
▸ SNCA P37840 2/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL16620943 1.00 APP (0.43) APPALDH1A1SNCA
SCHEMBL16335431 0.89 — —
SCHEMBL14330126 0.89 — —
SCHEMBL13893498 0.77 ALDH1A1 (0.32) ALDH1A1
SCHEMBL9244034 0.75 APP (0.30) APP
SCHEMBL20647129 0.73 APP (0.40) APPSNCA
SCHEMBL8411026 0.70 APP (0.36) APP
SCHEMBL24595282 0.70 TSHR (0.30) —
SCHEMBL9361086 0.70 KDM4E (0.35) APPALDH1A1
SCHEMBL9361093 0.70 KDM4E (0.35) APPALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20190070320-A1 ORGANOMEDICINALS FOR IMAGING AND TREATMENT OF NEURODEGENERATIVE DISORDERS WASHINGTON UNIVERSITY 2019-03-07 — — US claimed
US-20160213792-A1 HETEROCYCLIC MOLECULES FOR BIOMEDICAL IMAGING AND THERAPEUTIC APPLICATIONS NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT 2016-07-28 — — US claimed
US-10335504-B2 Heterocyclic molecules for biomedical imaging and therapeutic applications WASHINGTON UNIVERSITY (US) 2019-07-02 — — US disclosed
US-20190070320-A1 ORGANOMEDICINALS FOR IMAGING AND TREATMENT OF NEURODEGENERATIVE DISORDERS WASHINGTON UNIVERSITY 2019-03-07 — — US disclosed
US-20160213792-A1 HETEROCYCLIC MOLECULES FOR BIOMEDICAL IMAGING AND THERAPEUTIC APPLICATIONS NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT 2016-07-28 — — US disclosed
WO-2015051188-A1 HETEROCYCLIC MOLECULES FOR BIOMEDICAL IMAGING AND THERAPEUTIC APPLICATIONS WASHINGTON UNIVERSITY (US) 2015-04-09 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-10335504-B2 Heterocyclic molecules for biomedical imaging and therapeutic applications APP, PSEN1, BACE1 APP 1/4885ALDH1A1 2007/4885SNCA 124/4885
US-20190070320-A1 ORGANOMEDICINALS FOR IMAGING AND TREATMENT OF NEURODEGENERATIVE DISORDERS TARDBP, GRN, FUS APP 101/4885ALDH1A1 4277/4885SNCA 17/4885
US-20160213792-A1 HETEROCYCLIC MOLECULES FOR BIOMEDICAL IMAGING AND THERAPEUTIC APPLICATIONS APP, PSEN1, BACE1 APP 1/4885ALDH1A1 2007/4885SNCA 124/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback